company background image
M8W logo

MediWound DB:M8W Stock Report

Last Price

€15.40

Market Cap

€136.8m

7D

13.2%

1Y

46.7%

Updated

24 Mar, 2024

Data

Company Financials +

M8W Stock Overview

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally.

M8W fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MediWound Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MediWound
Historical stock prices
Current Share PriceUS$15.40
52 Week HighUS$15.40
52 Week LowUS$6.45
Beta0.94
1 Month Change28.33%
3 Month Change67.39%
1 Year Change46.67%
3 Year Change-47.37%
5 Year Change-50.00%
Change since IPO-74.80%

Recent News & Updates

Recent updates

Shareholder Returns

M8WDE PharmaceuticalsDE Market
7D13.2%3.0%1.3%
1Y46.7%-25.6%6.4%

Return vs Industry: M8W exceeded the German Pharmaceuticals industry which returned -24.2% over the past year.

Return vs Market: M8W exceeded the German Market which returned 7.5% over the past year.

Price Volatility

Is M8W's price volatile compared to industry and market?
M8W volatility
M8W Average Weekly Movement9.1%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: M8W's share price has been volatile over the past 3 months.

Volatility Over Time: M8W's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2000100Ofer Gonenhttps://www.mediwound.com

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.

MediWound Ltd. Fundamentals Summary

How do MediWound's earnings and revenue compare to its market cap?
M8W fundamental statistics
Market cap€136.80m
Earnings (TTM)-€6.21m
Revenue (TTM)€17.29m

7.9x

P/S Ratio

-22.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
M8W income statement (TTM)
RevenueUS$18.69m
Cost of RevenueUS$15.11m
Gross ProfitUS$3.58m
Other ExpensesUS$10.29m
Earnings-US$6.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.73
Gross Margin19.15%
Net Profit Margin-35.94%
Debt/Equity Ratio0%

How did M8W perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.